Table 1.

Patient Characteristics

Characteristic	Risedronate(n = 106)		Placebo(n = 106)		Total(n = 212)		P
	No.	%	No.	%	No.	%
Age, years
Mean	43.3		43.6		43.5		.46
SD	5.36		6.09		5.73
< 40	22	21	25	24	47	22	.77
40-49	73	69	68	64	141	67
≥ 50	11	10	13	12	24	11
ECOG performance score							.25
0	93	88	98	93	191	90
1	13	12	8	8	21	10
Planned tamoxifen							.72
Yes	62	59	59	56	121	57
No	24	23	29	27	53	25
Did not know	20	19	18	17	38	18
Planned taxane							.83
Yes	64	60	66	62	130	61
No	35	33	35	33	70	33
Did not know	7	7	5	5	12	3
Months since LMP							.45
1 to 3	96	91	99	93	195	92
> 3-6	10	9	7	7	17	8
Age at first menses, years							.50
Mean	12.6		12.7		12.6
SD	1.44		1.45		1.44
Age at first birth, years							.66
Mean	25.1		25.7		25.4
SD	6.29		5.66		5.98
Prior hysterectomy	10	9	5	5	15	7	.18
Prior oral contraceptive	32	30	37	35	69	33	.46
Years of prior OCP use							.90
Mean	8.5		8.4		8.5
SD	7.33		7.13		7.21
Chemotherapy groups
Anthracycline based	45	43	41	39	86	41	.60
Taxane based	4	4	3	3	7	3
Anthracycline + taxane based	55	52	62	59	117	55
Other	2	2	0	0	2	1

Abbreviations: SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; LMP, last menstrual period; OCP, oral contraceptive pills.